An experimental gene therapy developed by uniQure has, for the first time, shown a dramatic slowing of Huntington’s disease progression in human patients, offering hope for a condition long considered incurable.
How the Trial Worked
The therapy, called AMT-130, was administered via a one-time neurosurgical procedure lasting 12 to 20 hours using a modified viral vector to deliver corrective DNA to regions of the brain affected by the disease. Patients treated with a high dose saw their disease progress 75% more slowly over a 36-month period compared to matched external controls. Secondary outcomes showed a 60% slower decline in functional abilities. The treatment was generally well-tolerated, with no major new safety concerns reported.
Sarah Tabrizi, director of UCL’s Huntington’s Disease Centre, said these findings mark “We now have a treatment for one of the world’s more terrible diseases. This is absolutely huge. I’m really overjoyed.” uniQure now plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration in early 2026.
Regulatory Advances & Future Steps
Earlier in 2025, the FDA granted AMT-130 Breakthrough Therapy designation, which may expedite review and regulatory pathways. In a regulatory update, uniQure disclosed that it is aligning key analytic and manufacturing plans with FDA guidance ahead of the BLA submission.
The company intends to use external control data sets, like ENROLL-HD, for primary comparisons in its statistical analysis plan.
Why This Breakthrough Is So Significant
Disease-modifying therapy: Until now, Huntington’s treatments have only addressed symptoms; AMT-130 indicates the possibility of altering disease trajectory.
One-time administration: Because it is delivered via a single surgical procedure, its benefits—if durable—could last years without repeated dosing.
High unmet need: In the U.S., about 41,000 people live with Huntington’s and over 200,000 carry risk alleles.
Scientific validation: The magnitude of effect in this trial is among the most convincing in neurodegenerative disease research to date.
How AMT-130 Compares to Other Gene Therapies
AMT-130’s approach—one-time neurosurgical delivery of a vector designed to suppress the mutant huntingtin protein—is somewhat unique among genetic therapies, in both delivery method and disease target.
Here are some points of comparison:
Therapy
Mode of Delivery / Regimen
Indication / Age Group
Key Strengths
Known Limitations / Risks
AMT-130 (uniQure)
Single stereotactic brain surgery (direct striatal infusion)
Early-manifest Huntington’s disease
Promising stabilization of function, one-time treatment, demonstrable biomarker improvements
Surgical risks, inflammatory complications, durable long-term efficacy unknown
Zolgensma (Onasemnogene abeparvovec-AVXS-101)
Single intravenous or intrathecal in some trials
Spinal Muscular Atrophy (infants and older children)
Has shown dramatic improvements in survival, motor function; among best-known successful gene therapies
Very high cost, immune reactions, limited age window, administration logistics
Nusinersen (Spinraza)
Repeated intrathecal injections (ongoing)
SMA across age groups
Reduces disease burden, extends life, widely used; well-understood safety profile
Requires regular dosing, invasiveness, burdens on patients/caregivers, cost
Cautions and Limitations
Not a cure: While the slowing is impressive, it does not reverse the disease or fully stop its course.
Surgery risk and cost: The invasive nature and complexity of delivery limit its applicability, especially in less capable surgical settings.
Long-term durability unknown: Whether the effect holds beyond three years remains to be seen.
Regulatory and access hurdles: Approval does not guarantee access, and pricing, reimbursement, and manufacturing scale remain major challenges.
